J&J Hoping To Position Simeprevir As Top Next-Gen Protease Inhibitor For HCV
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The pharma’s Janssen unit recently received notification of priority review from FDA for its protease inhibitor simeprevir NDA; meanwhile, the company waits to see if its compound will be used in combination with Bristol’s daclatasvir or Gilead’s sofosbuvir.